Santhera CEO Exercises Options and Increases his Shareholding in Santhera Dienstag, 15. September 2015 - 07:10
Liestal, Switzerland, September 15, 2015 - Santhera Pharmaceuticals (SIX: SANN) announces that Thomas Meier, PhD, Chief Executive Officer of Santhera, has exercised all his vested options to acquire 104'394 registered shares of the Company. Of these, 70'000 shares were simultaneously sold to cover transaction and related tax expenses.
After the transaction, Dr. Meier's direct shareholding almost doubled from previously 38'508 shares to new 72'902 Santhera shares, representing an increase from 0.77% to 1.47% of the Company's share capital. Option exercise and related sale of shares have been disclosed to the SIX Swiss Exchange.
About Santhera:
Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® is authorized in the European Union for the treatment of Leber's Hereditary Optic Neuropathy (LHON). Santhera develops Raxone®/Catena® currently in two additional indications, Duchenne Muscular Dystrophy (DMD) and primary progressive Multiple Sclerosis (ppMS), and omigapil for Congenital Muscular Dystrophy (CMD), all areas of high unmet medical need. For further information, please visit the Company's websitewww.santhera.com.
Raxone® and Catena® are trademarks of Santhera Pharmaceuticals.
| For further information, contact: | |
| Thomas Meier, PhD, Chief Executive Officer | Christoph Rentsch, Chief Financial Officer |
| Phone +41 61 906 89 64 | Phone +41 61 906 89 65 |
| thomas.meier@santhera.com | christoph.rentsch@santhera.com |
| US investor contact: | US Public Relations contact: |
| Hans Vitzthum, LifeSci Advisors, LLC | Deanne Eagle, Planet Communications |
| Phone +1 212 915 2568 | Phone +1 917 837 5866 |
| hans@lifesciadvisors.com | deanne@planetcommunications.nyc |
Disclaimer / Forward-looking statements:
This press release may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.
# # #